Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF MEDICAL OFFICER | June 13, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,602 |
Ending reported balance
After 2024-06-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-13 · Exercise / conversion · Acquired 6,000 · Balance 11,602 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Row 2 · 2024-06-13 · Sale · Disposed 6,000 · Balance 5,602 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 83,510 |
Reported balance
After 2024-06-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-13 · Exercise / conversion · Disposed 6,000 · Balance 83,510 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
F2: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,103 | $19.50 | $41,008.50 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,103 | $1.74 | $3,659.22 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 13, 2023 Filed Dec 22, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $1.74 | $6,960.00 |
DisclosureSEC source: 0001415889-23-016908 · form4-12222023_061202.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| May 19, 2023 Filed May 23, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 65 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-008658 · form4-05232023_060501.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,953 Underlying: Common Stock · 65 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 19, 2023 Filed May 23, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 65 | $19.50 | $1,267.50 |
DisclosureSEC source: 0001415889-23-008658 · form4-05232023_060501.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| May 19, 2023 Filed May 23, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 65 | $1.74 | $113.10 |
DisclosureSEC source: 0001415889-23-008658 · form4-05232023_060501.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,090 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-008425 · form4-05192023_060504.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,018 Underlying: Common Stock · 1,090 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,090 | $19.59 | $21,355.83 |
DisclosureSEC source: 0001415889-23-008425 · form4-05192023_060504.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.50 to $19.665, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,090 | $1.74 | $1,896.60 |
DisclosureSEC source: 0001415889-23-008425 · form4-05192023_060504.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · balance_after: Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-006838 · form4-04252023_060401.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,108 Underlying: Common Stock · 4,000 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,000 | $19.50 | $78,000.00 |
DisclosureSEC source: 0001415889-23-006838 · form4-04252023_060401.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $1.74 | $6,960.00 |
DisclosureSEC source: 0001415889-23-006838 · form4-04252023_060401.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 18:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $25.57 | $0.00 |
DisclosureSEC source: 0001415889-23-002172 · form4-02082023_060201.xml · derivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2033-02-06 F2 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 65,433 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001493152-21-031753 · ownership.xml · derivative · entry 1 Gillies Hunter · CIK 0001868997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,433 Underlying: Common Stock · 65,433 shares Expires 2031-12-13 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:31 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 60,300 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-21-088378 · tm2121189-3_4seq1.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Stock · 60,300 shares Expires 2031-06-28 F5 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on June 29, 2022. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:31 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 109,640 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088378 · tm2121189-3_4seq1.xml · derivative · entry 2 Gillies Hunter · CIK 0001868997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,640 Underlying: Common Stock · 109,640 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F4 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:31 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 16,294 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088378 · tm2121189-3_4seq1.xml · derivative · entry 1 Gillies Hunter · CIK 0001868997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,294 Underlying: Common Stock · 16,294 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on May 2, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.